$1.6bn Agila injects strengths into Mylan

Mylan has snapped up Strides Arcolab's injectables arm, Agila Specialties, for $1.6 billion, plus $250 million in additional conditional payments, a transaction, which though seen as expensive, is expected to fast-track Mylan's approach towards becoming a top-three global player in the injectables space.

More from Anticancer

More from Therapeutic Category